乳腺癌新辅助化疗效果的病理评估
Pathological assessment after neoadjuvant chemotherapy in breast cancer
查看参考文献19篇
|
文摘
|
乳腺癌新辅助化疗是乳腺癌标准化治疗方法之一,因此,新辅助治疗后的病理评估以及评估的标准化非常重要。不同病理评估标准的主要区别在于pCR的定义不同。现阶段一般把ypT0/ is ypN0定义为pCR,即化疗后乳腺内可残留DCIS,但腋窝淋巴结内无癌细胞残留。笔者将着重介绍日本乳腺癌学会所采用的病理评估标准,并把该标准与美国MD Anderson癌症中心的残余肿瘤量(Residual Cancer Burden)系统、英国的Millar和Payne法,以及天津市肿瘤医院推荐的病理评估标准等进行比较。大量的临床研究表明,新辅助化疗后乳腺癌pCR者相比非pCR者,其DFS率和OS率均有明显提高。但是, pCR对于各种乳腺癌亚型的意义不尽相同,而pCR可能不是新辅助化疗的唯一预测因子。 |
|
其他语种文摘
|
Neoadjuvant chemotherapy is one of the standardized treatment methods for breast cancer. Pathological assessment and standardized evaluation after neoadjuvant therapy are very important. The main differences between the different criteria of pathological assessments are their definitions of pathologic complete response (pCR),which is currently generally defined as ypT0 /is ypN0,that is,residual ductal carcinoma in situ in the breast after chemotherapy,without residual cancer cells in the axillary lymph nodes. This paper introduces the histological response criteria of the Japanese Breast Cancer Society and compares it with the Residual Cancer Burden system of MD Anderson Cancer Center,the Millar and Payne method of the United Kingdom,and the pathologic evaluation standard recommended by Tianjin Cancer Hospital. A large number of clinical studies show that the DFS and OS of breast cancer patients with pCR are significantly higher than those of non-pCR patients after neoadjuvant chemotherapy. However,pCR has different meanings in different breast cancer subtypes and pCR may not be the only predictor in neoadjuvant chemotherapy. |
|
来源
|
中华乳腺病杂志（电子版）
,2018,12(5):257-262 【扩展库】
|
|
DOI
|
10.3877/cma.j.issn.1674-0807.2018.05.001
|
|
关键词
|
乳腺肿瘤
;
化疗疗法,辅助
;
病理学
|
|
地址
|
1.
日本大学医学部病态病理学系肿瘤病理学教研室, 东京, 173-8610
2.
天津医科大学肿瘤医院乳腺病理研究室, 300060
|
|
语种
|
中文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
1674-0807 |
|
学科
|
肿瘤学 |
|
文献收藏号
|
CSCD:6363137
|
参考文献 共
19
共1页
|
|
1.
Fisher E R. Pathobiology of preoperative chemotherapy findings from the National Surgical Adjuvant Breast and Bowel Project ( NSABP) Protocol B-18.
Cancer,2002,95(4):681-695
|
CSCD被引
35
次
|
|
|
|
|
2.
Bear H D. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
J Clin Oncol,2006,24(13):2019-2027
|
CSCD被引
57
次
|
|
|
|
|
3.
Mazouni C. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
J Clin Oncol,2007,25(19):2650-2655
|
CSCD被引
15
次
|
|
|
|
|
4.
Bossuyt V. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
Ann Oncol,2015,26(7):1280-1291
|
CSCD被引
4
次
|
|
|
|
|
5.
Cortazar P. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Lancet,2014,384(9938):164-172
|
CSCD被引
124
次
|
|
|
|
|
6.
von Minckwitz G. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
J Clin Oncol,2012,30(15):1796-1804
|
CSCD被引
59
次
|
|
|
|
|
7.
Symmans W F. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
J Clin Oncol,2007,25(28):4414-4422
|
CSCD被引
26
次
|
|
|
|
|
8.
Kuroi K. Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG.
Breast Cancer,2015,22(6):586-595
|
CSCD被引
1
次
|
|
|
|
|
9.
Kurosumi M. Histopathological criteria for assessment of therapeutic response in breast cancer.
Breast Cancer,2001,8(1):1-2
|
CSCD被引
2
次
|
|
|
|
|
10.
日本乳癌学会.
乳癌取り扱い規約. (17版),2012:84-85
|
CSCD被引
1
次
|
|
|
|
|
11.
Fukuda T. Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype.
Springerplus,2016,5:152
|
CSCD被引
5
次
|
|
|
|
|
12.
付丽.
乳腺疾病病理彩色图谱. (2版),2013:46-49
|
CSCD被引
1
次
|
|
|
|
|
13.
Ogston K N. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.
Breast,2003,12(5):320-327
|
CSCD被引
129
次
|
|
|
|
|
14.
Takei H. Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?.
Breast Cancer,2011,18(2):85-91
|
CSCD被引
2
次
|
|
|
|
|
15.
Baselga J. Lapatinib with trastuzumab for HER2-positive early breast cancer ( NeoALTTO): a randomised, open-label,multicentre,phase 3 trial.
Lancet,2012,379(9816):633-640
|
CSCD被引
42
次
|
|
|
|
|
16.
Peintinger F. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.
Mod Pathol,2015,28(7):913-920
|
CSCD被引
5
次
|
|
|
|
|
17.
Loibl S. Predictive factors for response to neoadjuvant therapy in breast cancer.
Oncol Res Treat,2014,37(10):563-568
|
CSCD被引
4
次
|
|
|
|
|
18.
Marinovich M L. Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy.
Br J Cancer,2013,109(6):1528-1536
|
CSCD被引
1
次
|
|
|
|
|
19.
Bae M S. Pretreatment MR imaging features of triple-negative breast cancer: association with response to neoadjuvant chemotherapy and recurrence-free survival.
Radiology,2016,281(2):392-400
|
CSCD被引
3
次
|
|
|
|
|
了解气象卫星更多信息，请访问